Holen Sie sich die Stockscreener-App
11.58
5.31%
-0.65
Handel nachbörslich:
11.75
0.17
+1.47%
Schlusskurs vom Vortag:
$12.23
Offen:
$12.18
24-Stunden-Volumen:
90,740
Relative Volume:
1.51
Marktkapitalisierung:
$69.03M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.4495
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+15.80%
1M Leistung:
+44.39%
6M Leistung:
+40.88%
1J Leistung:
+18.65%
1-Tages-Spanne:
$10.68
$12.18
1-Wochen-Bereich:
$10.15
$13.46
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
11.58 | 72.91M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsBuild wealth with high-performing stocks - jammulinksnews.com
What are the technical indicators suggesting about Atara Biotherapeutics Inc.Build wealth faster with disciplined trading - jammulinksnews.com
What is the dividend policy of Atara Biotherapeutics Inc. stockConsistently high yield - jammulinksnews.com
Why is Atara Biotherapeutics Inc. stock attracting strong analyst attentionUnlock high-yield investment opportunities - jammulinksnews.com
What catalysts could drive Atara Biotherapeutics Inc. stock higher in 2025Navigate the market with precision tools - jammulinksnews.com
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Should I hold or sell Atara Biotherapeutics Inc. stock in 2025Explosive capital gains - jammulinksnews.com
How Atara Biotherapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Rocket Pharmaceuticals (RCKT) and Atara Biotherapeutics (ATRA) - The Globe and Mail
What analysts say about Atara Biotherapeutics Inc. stockMarket-leading capital gains - Autocar Professional
What drives Atara Biotherapeutics Inc. stock priceExplosive capital appreciation - PrintWeekIndia
FDA accepts Atara’s BLA for tab-cel with priority review By Investing.com - Investing.com Nigeria
FDA accepts Atara’s BLA for tab-cel with priority review - Investing.com
Atara gets FDA priority review for Tabelecleucel application - Seeking Alpha
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News - GuruFocus
Atara Biotherapeutics stock jumps after FDA accepts BLA for tab-cel - Investing.com Australia
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority - GuruFocus
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
Innovation Ltd Panacea Buys 19,335 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock - Defense World
Atara Biotherapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Atara gains after insider purchase - MSN
Is Atara Biotherapeutics Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
Atara Biotherapeutics (ATRA) Shares Surge After Insider Purchase - GuruFocus
Atara stock gains after insider purchase (ATRA:NASDAQ) - Seeking Alpha
(ATRA) Trading Advice - news.stocktradersdaily.com
Why Atara Biotherapeutics Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyFree Consultation - Newser
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PR Newswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):